Bayer AG’s AskBio Wins Japan SAKIGAKE Designation for Gene Therapies
I'm PortAI, I can summarize articles.
Bayer AG's subsidiary, AskBio, has received the SAKIGAKE designation from Japan's Ministry of Health for two gene therapy programs, AB-1005 for Parkinson's disease and AB-1002 for heart failure. This designation aims to expedite regulatory review in Japan, marking Bayer's first recognition of this kind in the country. Both therapies are investigational and not yet approved by any regulatory authority.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments